![University of California, Los Angeles](https://trials-media.s3.amazonaws.com/orgs/university-of-california-los-angeles.jpeg)
Understanding the Mechanisms of Diastolic Dysfunction
Heart Failure With Preserved Ejection FractionHealthyHeart failure is a clinical syndrome marked by breathlessness, even at low levels of exertion, general fatigue, and fluid retention and is estimated to affect 5.1 million people in the United States. Heart failure with preserved ejection fraction (HFpEF) means that the heart pumps enough blood to the body, but patients still have terrible symptoms. It is estimated to account for about 50% of all heart failure cases. Experts agree that impaired filling of the heart, perhaps due to "stiffness" of the heart muscle itself, critically underlies HFpEF. There is currently no clinical technique for measuring heart muscle (myocardial) stiffness; the very definition of "myocardial stiffness" remains poorly established. Consequently, the ability to study the mechanisms that underlie HFpEF is virtually non-existent, and limited treatment options will persist without significant advances. The objective of this project is to use an Equilibrium-Material-Stability (EMS) framework that couples patient-specific clinical MRI and heart pressure data in a computational model of the heart to diagnose changes in myocardial stiffness. The central hypothesis is that the new EMS framework for understanding the mechanisms of diastolic dysfunction in HFpEF will be more sensitive and outperform currently available approaches.
![Lee's Pharmaceutical Limited](https://trials-media.s3.amazonaws.com/orgs/lees-pharmaceutical-limited.jpeg)
Evaluating Iron Protein Succinylate Oral Solution in Treating Chronic Heart Failure and Iron Deficiency...
Chronic Heart FailureIron-deficiencyThis study aims to evaluate the effect of standard heart failure therapy plus oral solution with protein succinylate iron compared to placebo on the primary end point of 6 minute walk distance at 24th week in patients with chronic ejection fraction reduction heart failure and iron deficiency.
![Loyola University](https://trials-media.s3.amazonaws.com/orgs/loyola-university.jpeg)
Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine
Heart FailureCardiogenic Shock1 moreThis is a randomized, double blind, single center trial to study of the effects of Ivabradine vs. Placebo on patients hospitalized for Stage D heart failure (HF)/ and cardiogenic shock (CS) who will require continuous infusion of Dobutamine and have developed sinus tachycardia (ST) (heart rate >100 beats/min). The aim of the study will be to assess the potential of Ivabradine to slow ST and improve hemodynamics in patients with stage D HF/CS on Dobutamine treatment.
![F. Javier Martin Sanchez](https://trials-media.s3.amazonaws.com/orgs/f-javier-martin-sanchez.jpeg)
Discharge Planning in Emergency Department for Frail Older With AHF
Acute Heart FailureFrail Elderly SyndromeObjectives: To demonstrate the efficacy of care transition holistic intervention (Multilevel Guided Discharge Planning, MGDP) in reducing 30-day adverse outcomes among frail older patients with acute heart failure (AHF) discharged from Emergency Departments (EDs) and to validate the results of MGDP in real life. Method: Investigators will select frail patients ≥70 years with primary diagnosis of AHF discharged from EDs. The intervention will consist of MGDP implementation: 1) checklist that includes clinical recommendations and resources activations; 2) scheduling of early visit with the specialist; 3) communication with primary care; 4) providing a written instruction sheet to patient or caregiver. Phase 1: matched-pair cluster randomized clinical trial. EDs were randomly allocated to intervention (n = 10) or control (n = 10) group. Investigators will compare the outcomes between intervention and control groups. Phase 2: a quasi-experimental study. The 20 EDs will carry out the intervention. Investigators will compare the outcomes between phase 1 and phase 2 of intervention group and between phase 1 and phase 2 of control group. The main outcome is a 30-day composite endpoint (ED revisit or hospital admission for AHF and cardiovascular death) after being discharged.
![Centro en Insuficiencia Cardiaca, Mexico](https://trials-media.s3.amazonaws.com/orgs/centro-en-insuficiencia-cardiaca-mexico.jpeg)
Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure...
Heart FailureCongestive Heart FailureIn the present study, consecutive patients, older than 18 years, of both genders will be included. The diagnosis of reduced Heart Failure (HfrEF) according to: Clinical pattern, laboratories and Cardiac imaging (ESC criteria). Treatment will be assigned in two groups: Bumetanide and another group will be received Indapamide. Each group received maximum tolerated dose for seven days with Clinical and labs evaluations will be every 48 hrs. (Face-to-face and/or telephone visits). Serum and urinary labs, EKG´s, Echo will be evaluated. Daily in-home register will made. Final points were: Mortality, Urinary failure, Clinical Impairment, Hospital admissions, Oedema. (MUCHO). All patients will be followed for 30 days.
![Federico II University](https://trials-media.s3.amazonaws.com/orgs/federico-ii-university.jpeg)
Treatment of GHD Associated With CHF
Heart FailureGrowth Hormone DeficiencyAim of the current study is to assess the cardiovascular effects of GH replacement therapy in patients with coexisting GHD and CHF
![Collegium Medicum w Bydgoszczy](https://trials-media.s3.amazonaws.com/orgs/collegium-medicum-w-bydgoszczy.jpeg)
Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic...
Systolic Heart FailureRehospitalizations due to exacerbation of chronic heart failure are an important problem for patients suffering from heart failure. Rehospitalzations lead to worse prognosis, have an impact on the quality of life and have a negative financial impact on the health care system. Currently, studies are being conducted on the efficacy of levosimendan in the prevention of heart failure exacerbations. Patients receive levosimendan at repetitive use and preliminary results suggest a reduction in the incidence of exacerbations of heart failure. Thanks to the clinical trial planned in the Department of Cardiology of the Biziel Hospital with repeatable use of levosimendan, it is possible to determine the benefits of this method of treatment more accurately.
![The Second Affiliated Hospital of Harbin Medical University](https://trials-media.s3.amazonaws.com/orgs/the-second-affiliated-hospital-of-harbin-medical-university.jpeg)
Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease(CKD)Patients...
CKDThis paper will mainly present the renal results from a clinical study aimed to observe the effect of sacubitril/valsartan in advanced chronic kedney disease patients with heart failure.All patients will receive LCZ696.The results will be compared before and after treatment.
![University of Sao Paulo General Hospital](https://trials-media.s3.amazonaws.com/orgs/university-of-sao-paulo-general-hospital.jpeg)
Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment...
Insufficiency;CardiacCancer2 moreNew therapies for cancer increased patient survival, but led to the recognition of adverse effects associated with cancer treatment, such as the use of chemotherapy. Cardiotoxicity is the most significant adverse effect, which affect the functional capacity and quality of life and is associated with high morbidity and mortality, regardless of the oncological prognosis. One of the manifestations of cardiotoxicity is ventricular dysfunction that can lead to heart failure. Neuro humoral hyperactivation with increased sympathetic nerve activity is a typical manifestation of heart failure and is associated with worse prognosis. Studies have shown that physical training significantly reduces sympathetic nerve activity in addition to improving muscle blood flow, reversing effects on skeletal muscle and improving quality of life. The hypothesis is that physical training may reduce sympathetic nerve activity and vasoconstrictor status in patients with heart failure caused by anthracyclines, as well as improving baroreflex and chemoreflex sensibility, mechanoreflex and metaborreflex control and skeletal myopathy.
![Isfahan University of Medical Sciences](https://trials-media.s3.amazonaws.com/orgs/isfahan-university-of-medical-sciences.jpeg)
Effect of Melatonin on Cardiovascular and Muscle Mass and Function in Patients With Heart Failure...
Heart Failure With Reduced Ejection FractionThe main aim of this study is to investigate the effect of melatonin on clinical outcome, quality of life, and cardiovascular function of the patients with heart failure, as well as its effect on their skeletal muscle mass and function.